Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020

EMERYVILLE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. ADMS today announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Investor Conference Call and Webcast

The conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and  (484) 747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at ir.adamaspharma.com/events-presentations and will be available for replay until May 25, 2020.

About Adamas Pharmaceuticals, Inc.

At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.

Contact

Investors:

Peter Vozzo

Managing Director, Westwicke

443-213-0505

peter.vozzo@westwicke.com

Media:

Sarah Mathieson

Vice President, Corporate Communications

510-450-3528

smathieson@adamaspharma.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!